Skip to main content

Advertisement

SpringerLink
Log in

Loss of Lean Body Mass as an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer

  • Gastrointestinal Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

An Erratum to this article was published on 14 July 2015

Abstract

Background and Aims

Compliance with S-1 adjuvant chemotherapy is not satisfactory, and the aim of the present study was to clarify risk factors for the continuation of S-1 after gastrectomy.

Methods

This retrospective study selected patients who underwent curative D2 surgery for gastric cancer, were diagnosed with stage II/III disease, had a creatinine clearance >60 ml/min, and received adjuvant S-1 at our institution between June 2010 and March 2014. The time to S-1 treatment failure (TTF) was calculated.

Results

Fifty-eight patients were selected for the present study. When the TTF curves stratified by each clinical factor were compared using the log-rank test, lean body-mass loss (LBL) of 5 % was regarded as a critical cutoff point. Univariate Cox’s proportional hazard analyses demonstrated that LBL was a significant independent risk factor for continuation. The 6-month continuation rate was 91.7 % in patients with an LBL < 5 %, and 66.3 % for patients with an LBL > 5 % (p = 0.031).

Conclusions

The present study demonstrated that LBL might be an important risk factor for a decrease in compliance to adjuvant chemotherapy with S-1 in patients with stage II/III gastric cancer who underwent D2 gastrectomy. A multicenter, double-blinded, prospective cohort study is necessary to confirm whether LBL would affect adjuvant S-1 continuation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.

    Article  PubMed  Google Scholar 

  2. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.

    Article  CAS  PubMed  Google Scholar 

  3. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomized controlled trial. Lancet. 2012;379:315–21.

    Article  CAS  PubMed  Google Scholar 

  4. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 1981;304:101–5.

    Article  Google Scholar 

  5. Aoyama T, Yoshikawa T, Shirai J, Hayashi T, Yamada T, Tsuchida K, et al. Body weight loss after surgery is an independent risk factor for continuation of S-1 adjuvant chemotherapy for gastric cancer. Ann Surg Oncol. 2013;20:2000-6.

    Article  PubMed  Google Scholar 

  6. Fein M, Fuchs KH, Thalheimer A, Freys SM, Heimbucher J, Thiede A. Long-term benefits of Roux-en-Y pouch reconstruction after total gastrectomy: a randomized trial. Ann Surg. 2008;247:759–65.

    Article  PubMed  Google Scholar 

  7. Lassen K, Soop M, Nygren J, Cox PB, Hendry PO, Spies C, et al. Consensus review of optimal perioperative care in colorectal surgery: Enhanced Recovery After Surgery (ERAS) Group recommendations. Arch Surg. 2009;144:961–969.

    Article  PubMed  Google Scholar 

  8. Yamada T, Hayashi T, Aoyama T, Shirai J, Fujikawa H, Cho H, et al. Feasibility of enhanced recovery after surgery in gastric surgery: a retrospective study. BMC Surg. 2014;14:41.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Morgan DJ, Bray KM. Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin Pharmacokinet. 1994;26:292-307.

    Article  CAS  PubMed  Google Scholar 

  10. Roubenoff R, Kehayias JJ. The meaning and measurement of lean body mass. Nutr Rev. 1991;49:163-75.

    Article  CAS  PubMed  Google Scholar 

  11. Mitsiopoulos N, Baumgartner RN, Heymsfield SB, et al. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol. 1998;85:115-22.

    CAS  PubMed  Google Scholar 

  12. Lorenzo AD, Andreoli A. Segmental bioelectrical impedance analysis. Curr Opin Clin Nutr Metab Care. 2003;6:551-5.

    Article  PubMed  Google Scholar 

  13. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.

    Article  Google Scholar 

  14. Aoyama T, Yoshikawa T, Hayashi T, Kuwabara H, Mikayama Y, Ogata T, et al. Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for gastric cancer. Gastric Cancer. 2012;16:133-9.

    Article  PubMed  Google Scholar 

  15. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14: 113-23.

    Article  Google Scholar 

  16. Yamada T, Hayashi T, Cho H, Yoshikawa T, Taniguchi H, Fukushima R, et al. Usefulness of enhanced recovery after surgery protocol as compared with conventional perioperative care in gastric surgery. Gastric Cancer. 2012;15:34–41.

    Article  PubMed  Google Scholar 

  17. Yoshikawa T, Rino Y, Yukawa N, Oshima T, Tsuburaya A, Masuda M. Neoadjuvant chemotherapy for gastric cancer in Japan: a standing position by comparing with adjuvant chemotherapy. Surg Today. 2014;44:11-21.

    Article  CAS  PubMed  Google Scholar 

  18. Kiyama T, Mizutani T, Okuda T, Fujita I, Tokunaga A, Tajiri T, et al. Postoperative changes in body composition after gastrectomy. J Gastrointest Surg. 2005;9:313-9.

    Article  PubMed  Google Scholar 

  19. Prado CM, Baracos VE, McCargar LJ, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res. 2007;13:3264-8.

    Article  CAS  PubMed  Google Scholar 

  20. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patientswith solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9:629-35.

    Article  PubMed  Google Scholar 

  21. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009;15:2920-6.

    Article  CAS  PubMed  Google Scholar 

  22. Aslani A, Smith RC, Allen BJ, Pavlakis N, Levi JA. The predictive value of body protein for chemotherapy induced toxicity. Cancer. 2000;88:796-803.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported in part by a non-governmental organization, the Kanagawa Standard Anti-Cancer Therapy Support System. The authors express their sincere gratitude to Mrs. Rika Takahashi for her excellent data management.

Disclosure

Toru Aoyama, Taiichi Kawabe, Hirohito Fujikawa, Tsutomu Hayashi, Takanobu Yamada, Kazuhito Tsuchida, Norio Yukawa, Takashi Oshima, Yasushi Rino, Munetaka Masuda, Takashi Ogata, Haruhiko Cho, and Takaki Yoshikawa declare no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan

    Toru Aoyama MD, Taiichi Kawabe MD, Hirohito Fujikawa MD, Tsutomu Hayashi MD, Takanobu Yamada MD, Kazuhito Tsuchida MD, Takashi Ogata MD, PhD, Haruhiko Cho MD & Takaki Yoshikawa MD, PhD

  2. Department of Surgery, Yokohama City University, Yokohama, Japan

    Toru Aoyama MD, Taiichi Kawabe MD, Hirohito Fujikawa MD, Tsutomu Hayashi MD, Takanobu Yamada MD, Kazuhito Tsuchida MD, Norio Yukawa MD, Takashi Oshima MD, PhD, Yasushi Rino MD, Munetaka Masuda MD, PhD & Takaki Yoshikawa MD, PhD

Authors
  1. Toru Aoyama MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Taiichi Kawabe MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hirohito Fujikawa MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tsutomu Hayashi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takanobu Yamada MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kazuhito Tsuchida MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Norio Yukawa MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Takashi Oshima MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yasushi Rino MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Munetaka Masuda MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Takashi Ogata MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Haruhiko Cho MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Takaki Yoshikawa MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takaki Yoshikawa MD, PhD.

Additional information

Toru Aoyama and Takaki Yoshikawa have contributed equally to this study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aoyama, T., Kawabe, T., Fujikawa, H. et al. Loss of Lean Body Mass as an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer. Ann Surg Oncol 22, 2560–2566 (2015). https://doi.org/10.1245/s10434-014-4296-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-014-4296-z

Keywords

Search

Navigation